Ofatumumab
From Proteopedia
(Difference between revisions)
| Line 4: | Line 4: | ||
* Major Indication: Chronic Lymphocytic [[Cancer|Leukemia]] | * Major Indication: Chronic Lymphocytic [[Cancer|Leukemia]] | ||
* Drug Class: Anti-CD20 [[Monoclonal Antibody]] | * Drug Class: Anti-CD20 [[Monoclonal Antibody]] | ||
| - | * Date of FDA Approval: 2009 (2023) | + | * Date of FDA Approval (Patent Expiration): 2009 (2023) |
* 2009 Sales: $3.1 Billion | * 2009 Sales: $3.1 Billion | ||
* | * | ||
Revision as of 07:32, 14 December 2010
|
Better Known as: Arzerra
- Marketed By: Genmab & GlaxoSmithKline
- Major Indication: Chronic Lymphocytic Leukemia
- Drug Class: Anti-CD20 Monoclonal Antibody
- Date of FDA Approval (Patent Expiration): 2009 (2023)
- 2009 Sales: $3.1 Billion
- See Pharmaceutical Drugs for more information about other drugs and diseases.
Mechanism of Action
References
